Qiagen (NYSE:QGEN) Stock Holdings Lifted by XTX Topco Ltd

XTX Topco Ltd lifted its holdings in shares of Qiagen (NYSE:QGEN - Free Report) by 129.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,192 shares of the company's stock after purchasing an additional 11,385 shares during the quarter. XTX Topco Ltd's holdings in Qiagen were worth $920,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in QGEN. Massmutual Trust Co. FSB ADV raised its position in shares of Qiagen by 39.8% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company's stock worth $39,000 after buying an additional 243 shares during the period. CWM LLC raised its position in Qiagen by 12.0% in the second quarter. CWM LLC now owns 2,505 shares of the company's stock valued at $103,000 after purchasing an additional 269 shares during the period. Zurich Insurance Group Ltd FI raised its position in Qiagen by 5.7% in the third quarter. Zurich Insurance Group Ltd FI now owns 5,291 shares of the company's stock valued at $239,000 after purchasing an additional 287 shares during the period. National Bank of Canada FI raised its position in Qiagen by 1.2% in the third quarter. National Bank of Canada FI now owns 25,636 shares of the company's stock valued at $1,155,000 after purchasing an additional 308 shares during the period. Finally, Atria Investments Inc raised its position in Qiagen by 6.0% in the third quarter. Atria Investments Inc now owns 7,632 shares of the company's stock valued at $348,000 after purchasing an additional 433 shares during the period. Institutional investors and hedge funds own 70.00% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on QGEN shares. HSBC lowered Qiagen from a "buy" rating to a "hold" rating and set a $49.00 price objective on the stock. in a research report on Thursday, October 17th. Hsbc Global Res raised Qiagen to a "hold" rating in a research report on Thursday, October 17th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $54.00 price objective (up from $42.00) on shares of Qiagen in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $51.15.

Qiagen Stock Performance

Shares of NYSE QGEN traded up $0.09 during midday trading on Wednesday, hitting $46.16. 734,787 shares of the company's stock were exchanged, compared to its average volume of 1,139,661. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The stock's 50 day moving average price is $43.13 and its 200-day moving average price is $43.68. The firm has a market cap of $10.53 billion, a P/E ratio of 118.36, a PEG ratio of 3.37 and a beta of 0.35. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.